Focus on preventing and treating comorbidities with conventional therapies (metformin, insulin for diabetes mellitus, lipid-lowering drugs for dyslipidemia) [6].Close cardiac monitoring given the high incidence of cardiac manifestations [12].Experimental use of metreleptin considered for hypoleptinemic patients with severe metabolic derangements in the United States, with clinical trials available [5]. In Europe and Japan patients, those not responsive to conventional treatment can be prescribed metreleptin [5]. The gene discussed is INS; the disease is metabolic syndrome.